In this 52-week trial, bempedoic acid added to maximally tolerated statin therapy did not lead to a higher incidence of overall adverse events than placebo and led to significantly lower LDL cholesterol levels. (Funded by Esperion Therapeutics; CLEAR Harmony ClinicalTrials.gov number, NCT02666664.).
No takes yet. Share an insight, caveat, or question.
Ray et al. (2019) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: